Inari Medical Inc. (NARI): Price and Financial Metrics
NARI Price/Volume Stats
Current price | $41.63 | 52-week high | $71.85 |
Prev. close | $40.65 | 52-week low | $39.90 |
Day low | $40.39 | Volume | 1,011,900 |
Day high | $42.23 | Avg. volume | 923,834 |
50-day MA | $54.05 | Dividend yield | N/A |
200-day MA | $59.46 | Market Cap | 2.41B |
NARI Stock Price Chart Interactive Chart >
NARI POWR Grades
- Growth is the dimension where NARI ranks best; there it ranks ahead of 96.25% of US stocks.
- NARI's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
- NARI's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).
NARI Stock Summary
- NARI's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,148 -- higher than 97.09% of US-listed equities with positive expected earnings growth.
- Price to trailing twelve month operating cash flow for NARI is currently 104.17, higher than 97.36% of US stocks with positive operating cash flow.
- Over the past twelve months, NARI has reported earnings growth of -114.5%, putting it ahead of merely 11.84% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to INARI MEDICAL INC are PRGO, SJM, DDOG, JCTCF, and NRDS.
- Visit NARI's SEC page to see the company's official filings. To visit the company's web site, go to www.inarimedical.com.
NARI Valuation Summary
- In comparison to the median Healthcare stock, NARI's price/earnings ratio is 4731.9% lower, now standing at -1350.2.
- Over the past 44 months, NARI's price/earnings ratio has gone up 293.2.
Below are key valuation metrics over time for NARI.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
NARI | 2023-12-29 | 8.0 | 8.3 | -1350.2 | 1308.9 |
NARI | 2023-12-28 | 8.0 | 8.3 | -1354.4 | 1313.0 |
NARI | 2023-12-27 | 8.1 | 8.4 | -1368.5 | 1326.9 |
NARI | 2023-12-26 | 7.9 | 8.2 | -1337.1 | 1296.0 |
NARI | 2023-12-22 | 8.1 | 8.4 | -1366.7 | 1325.1 |
NARI | 2023-12-21 | 8.0 | 8.3 | -1360.6 | 1319.1 |
NARI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NARI has a Quality Grade of B, ranking ahead of 85.55% of graded US stocks.
- NARI's asset turnover comes in at 0.917 -- ranking 23rd of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows NARI's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.917 | 0.921 | 0.292 |
2021-03-31 | 0.774 | 0.912 | 0.271 |
2020-12-31 | 0.794 | 0.906 | 0.292 |
NARI Price Target
For more insight on analysts targets of NARI, see our NARI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $119.67 | Average Broker Recommendation | 1.33 (Strong Buy) |
Inari Medical Inc. (NARI) Company Bio
Inari Medical, Inc. operates as a medical device company. It develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.
Latest NARI News From Around the Web
Below are the latest news stories about INARI MEDICAL INC that investors may wish to consider to help them evaluate NARI as an investment opportunity.
Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceIRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relatio |
Reasons to Retain Inari Medical (NARI) in Your Portfolio NowInari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern. |
Why Is Steris (STE) Down 3.4% Since Last Earnings Report?Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Inari Medical, Inc. (NARI) Up 17.1% Since Last Earnings Report: Can It Continue?Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient OutcomeInari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally. |
NARI Price Returns
1-mo | -28.76% |
3-mo | -36.41% |
6-mo | -37.29% |
1-year | -35.62% |
3-year | -61.55% |
5-year | N/A |
YTD | -35.87% |
2023 | 2.14% |
2022 | -30.36% |
2021 | 4.56% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...